Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 566

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 566
---
 of OmnigenicsAI. In exchange for this contribution, OmnigenicsAI issued 30,000,000shares with a par value of US$0.0001 per share to Heritas Ltd., thereby completing the reorganization. This entailed, in the year ended June 30, 2024, a reduction of the share capital from US$13,059 to US$3,000. The effect of the reduction in share capital by US$10,059 and the related inflation adjustment on share capital of US$39,826 was impacted by an offsetting in share premium in accordance with the movement identified as “Reorganization effects” in the Combined Statement of Changes in Shareholders’ Deficit. On March 25, 2024, the Company entered into a Business Combination Agreement (“BCA”) with APx Acquisition Corp. I (“SPAC”), Heritas Merger Sub Limited and MultiplAI Health Ltd., a private limited company formed under the laws of England and Wales, to effectuate a business combination. The transaction, designed to transition OmnigenicsAI into a publicly traded entity, involves the merger of Heritas Merger Sub Limited, a wholly -ownedsubsidiary of OmnigenicsAI incorporated in the Cayman Islands, with and into SPAC, a company also incorporated in the Cayman Islands, with SPAC continuing as the surviving entity and becoming a wholly -ownedsubsidiary of OmnigenicsAI. As part of the transaction, all SPAC shares and warrants will convert into equity in OmnigenicsAI, pursuant to the terms of the BCA. Within the framework of the BCA, an agreement has been reached, which is conditional on the closing of the BCA. If this were to occur, a restructuring of intercompany debt will be carried out between Heritas Argentina and Heritas Ltd. The restructuring involves the forgiveness of certain intercompany loans (in whose the lender is Heritas Ltd., see Note 20), which will be accounted for as capital contributions without issuing additional equity. Besides, the agreement outlines pre -mergerconditions, including SPAC shareholder redemption rights and the restructuring of OmnigenicsAI’s corporate structure to align with transaction objectives. Post -merger, OmnigenicsAI’s governance structure will include a newly constituted board of directors with representation from the participating entities, and SPAC will continue its operations under OmnigenicsAI’s oversight. However, after the reporting period, on August 27, 2024, Heritas Ltd. and Multi